Human Papillomavirus Prevalence and Vaccination Rates Among Users of Pre-Exposure Prophylaxis for Human Immunodeficiency Virus Prevention.
Paul RotertChristopher WheldonJenn KownackZoe Sullivan-BlumBrendan CokingtinKarishma KhetaniKavindu NdetiKevin J SykesMegha RamaswamyPublished in: Journal of primary care & community health (2022)
Despite ongoing risk of HPV infection and frequent interaction with the medical system, this study found most PrEP users continue to be unvaccinated. This is a significant missed opportunity for HPV prevention. With the FDA approval of the HPV vaccine for individuals age 9 to 45, PrEP patients in this age range would benefit from clinicians partnering HPV vaccination with PrEP prescribing.
Keyphrases
- human immunodeficiency virus
- high grade
- men who have sex with men
- hepatitis c virus
- end stage renal disease
- cervical cancer screening
- antiretroviral therapy
- newly diagnosed
- primary care
- ejection fraction
- healthcare
- chronic kidney disease
- hiv infected
- prognostic factors
- risk factors
- hiv aids
- patient reported outcomes